Substance and claimed effects

A hangover cure is anything taken before, during, or after a drinking session with the intent of preventing or shortening the constellation of symptoms that follow alcohol intoxication once blood alcohol returns to zero. The hangover itself is characterised by headache, fatigue, nausea, gastrointestinal upset, photophobia and phonophobia, tremor, sweating, tachycardia, cognitive impairment, and the dysphoric / anxious state colloquially called "hangxiety"; it typically peaks 12–14 hours after peak blood alcohol concentration and resolves within 24 hours Verster et al. 2020, Penning et al. 2010.

The class of remedies covered by the brief: (1) the hair-of-the-dog drink — more alcohol the next morning; (2) greasy or fatty food before, during, or after drinking; (3) rehydration with water and electrolyte solutions; (4) over-the-counter painkillers (acetaminophen / paracetamol, NSAIDs); (5) branded supplements marketed for hangover prevention or relief (dihydromyricetin, N-acetylcysteine, prickly pear extract, Korean pear juice, artichoke, B-complex, charcoal, "pre-tox" kits). Claims attached to these range from "reduces severity" through "shortens duration" to "prevents hangover entirely". The entry rates these claims against the trial literature and against the underlying pathophysiology.

Holistic consequences this entry must cover: health_short_term (avoiding acetaminophen hepatotoxicity, getting symptom relief without harm), longevity (the meta-finding that the only effective "cure" is drinking less, which is itself a longevity intervention), energy and focus (next-day cognitive and psychomotor deficits are real and measurable), mood (hangxiety, irritability), cost_burden (branded supplements run $1–4 per dose), and evidence (a small but real RCT literature with one Cochrane-adjacent systematic review).

Evidence by addressing question

mechanism

The hangover is not one mechanism. The modern consensus — formalised by the Alcohol Hangover Research Group — is that it is the residual signature of several overlapping insults that peak as blood alcohol clears Penning et al. 2010, Mackus et al. 2020, Verster et al. 2020.

Acetaldehyde toxicity. Ethanol is oxidised by alcohol dehydrogenase to acetaldehyde, a reactive carbonyl that binds proteins, depletes glutathione, and triggers nausea, flushing, and tachycardia; aldehyde dehydrogenase 2 (ALDH2) then converts it to acetate. Roughly 540 million people of East Asian ancestry carry a loss-of-function ALDH2 variant that slows acetaldehyde clearance and produces both the "Asian flush" phenotype and disproportionately severe hangovers at small doses Mackus et al. 2020. Peak acetaldehyde concentrations correlate with severity in non-flush populations as well.

Inflammatory response. Acute alcohol intake provokes a measurable systemic cytokine response — elevated IL-6, IL-10, TNF-α, and CRP the morning after — and morning hangover severity tracks these markers more reliably than it tracks blood ethanol the night before van de Loo et al. 2020. Mechanism candidates include ethanol-driven increases in gut permeability allowing portal-vein endotoxin (LPS) translocation, direct hepatic cytokine release, and acetaldehyde-protein adduct formation. The inflammatory model now anchors most pharmacologic-target speculation in the field.

Sleep disruption. Ethanol shortens sleep-onset latency and increases first-half slow-wave sleep, then fragments the second half with arousals and suppressed REM, particularly at doses above 0.5 g/kg Ebrahim et al. 2013. Subjects report "8 hours" but record sleep architecture closer to broken 5–6 hours. This contributes substantially to next-day fatigue, mood, and cognitive impairment independent of acetaldehyde or inflammation.

GABA / glutamate rebound. Alcohol potentiates GABA-A receptors and inhibits NMDA glutamate receptors during intoxication; as it clears, the system overshoots into a hyperexcitable, glutamate-dominant state — the same mechanism that drives full alcohol withdrawal in dependent drinkers. In social drinkers this manifests as morning anxiety, tremor, and photophobia Penning et al. 2010, Verster 2008.

Mild dehydration and electrolytes. Ethanol suppresses arginine vasopressin (ADH), increasing free-water clearance; consumed at 1 g/kg it produces a measurable net negative fluid balance and small electrolyte losses. The historical "dehydration is the hangover" model overstates this: controlled studies find no consistent correlation between hydration biomarkers (urine specific gravity, plasma osmolality, vasopressin) and reported hangover severity Stock et al. 2014. Dehydration plausibly contributes to headache and dry mouth but does not appear to be the central mechanism.

Hypoglycaemia. Ethanol oxidation consumes NAD+ and inhibits gluconeogenesis. In well-nourished social drinkers this is modest and clinically silent; in fasted, malnourished, or heavy drinkers it can produce frank hypoglycaemia and contributes to morning weakness and tremor Penning et al. 2010.

Congeners. Distillation by-products in darker drinks — methanol, furfural, fusel oils, tannins, histamine — independently increase hangover severity. In a same-drinker comparison of bourbon and vodka at matched ethanol dose, the bourbon group reported substantially worse hangovers; methanol clearance lags ethanol clearance and competes for the same enzymes, producing residual formaldehyde / formic acid exposure that may contribute Rohsenow & Howland 2010. Beer-then-wine versus wine-then-beer order, however, has no effect — formally tested in a 90-subject crossover trial Köchling et al. 2019.

evidence

The defining piece of evidence in this entry is a 2005 BMJ systematic review of randomised controlled trials of hangover interventions Pittler et al. 2005. The review identified eight RCTs covering propranolol, tropisetron, tolfenamic acid, glucose / fructose, borage, artichoke, prickly pear (Opuntia ficus-indica), and a yeast-based preparation. Conclusion: "No compelling evidence exists to suggest that any conventional or complementary intervention is effective for preventing or treating alcohol hangover." A 2017 systematic review using updated criteria — Jayawardena, Verster, et al. — reached substantively the same verdict on a wider set of trials, including dihydromyricetin, red ginseng, NAC, and several proprietary formulations: most trials are small, methodologically weak, and rarely replicated Jayawardena et al. 2017, Verster & Penning 2010.

The individual trials worth naming:

• Prickly pear (Opuntia ficus-indica) extract — 55 subjects, double-blind crossover; 5 hours pre-drinking dosing reduced overall hangover severity by ~2.7 points on an 0–10 composite, with strongest effects on nausea, dry mouth, and anorexia. Plasma CRP was suppressed compared with placebo, consistent with the inflammatory model. Headache was not significantly affected Wiese et al. 2004. This is the best single positive trial in the literature.
• Artichoke extract — 15 healthy volunteers, randomised crossover, capsules before and after drinking. No effect on any hangover symptom Pittler et al. 2003.
• Korean pear juice — small RCT (n=14, crossover) by the CSIRO and Korean groups: 220 mL of pear juice pre-drinking reduced overall hangover severity and specifically the symptoms of trouble concentrating, by mechanisms that may include induction of acetaldehyde dehydrogenase activity Mun et al. 2015.
• Dihydromyricetin (DHM) — flavonoid from Hovenia dulcis, marketed widely in Asian and US "anti-hangover" supplements. The single most-cited preclinical paper showed that DHM blocked alcohol intoxication and withdrawal symptoms in rats and antagonised ethanol's effect at GABA-A receptors Shen et al. 2012. Human RCTs are sparse, small, and show modest or null effects on hangover symptoms; the supplement-industry narrative outruns the trial base.
• N-acetylcysteine (NAC) — biologically plausible as a glutathione precursor that should scavenge acetaldehyde; trial evidence in humans for hangover specifically is thin to absent. Animal data and indirect evidence in alcoholic hepatitis have been extrapolated.

Painkillers. No RCT has formally tested whether ibuprofen or aspirin shortens hangover, but both reduce headache as expected; this is folk-clinical use, not trial-grounded. The pharmacovigilance literature on acetaminophen (paracetamol) combined with alcohol is the load-bearing piece: chronic alcohol exposure induces CYP2E1, which oxidises acetaminophen to the hepatotoxic metabolite NAPQI; even therapeutic doses (2–4 g/day) have been implicated in fulminant hepatic failure in moderate drinkers, especially when fasted Whitcomb & Block 1994, Draganov et al. 2000. The risk is not a quirk of alcoholics; even social drinkers who take acetaminophen during or after drinking are exposed.

Hair of the dog. No controlled trial. The pharmacological rationale — methanol/ethanol enzymatic competition; delay of GABA/glutamate rebound — is real but only defers the hangover and exposes the drinker to additional ethanol and a near-textbook pathway to dependence. No clinical guideline endorses it.

Greasy food. No effect on hangover treatment. Eaten before drinking, fatty / protein-rich meals slow gastric emptying and reduce peak BAC by roughly 30–50%, which reduces the dose that produces hangover; this is a "drink less, effectively" effect, not a cure Penning et al. 2010.

Hydration / electrolytes. Controlled human studies find no relationship between hydration status and hangover severity Stock et al. 2014. Rehydration treats specific dehydration-driven symptoms (thirst, dry mouth, mild headache) without changing overall severity or duration.

misconceptions

Three claims dominate lay advice and survive poorly under trial scrutiny:

• "Hangovers are dehydration." Mostly false. Vasopressin suppression and modest fluid loss are real, but hangover severity does not track hydration biomarkers in controlled studies Stock et al. 2014. The hangover persists in adequately hydrated subjects.
• "Beer before liquor, never sicker." False, in a formally controlled trial. The three-arm Köchling study (n=90, crossover) found that drink order had no effect on hangover severity; the only predictor was how drunk you got and how you felt at the end of the night Köchling et al. 2019.
• "Tylenol for the headache." Worse than false — actively dangerous. Acetaminophen plus alcohol depletes hepatic glutathione, and the CYP2E1 induction caused by alcohol shifts paracetamol metabolism toward NAPQI; case series implicate even therapeutic acetaminophen doses in hepatotoxicity in regular drinkers, especially when fasted Whitcomb & Block 1994, Draganov et al. 2000.

Less consequential but worth flagging: the idea that congeners are irrelevant (false — controlled comparisons show a clear bourbon-vs-vodka effect at matched alcohol dose Rohsenow & Howland 2010); the idea that "sweating it out" via exercise or sauna shortens hangover (no controlled evidence; alcohol does not exit through sweat in meaningful quantities); the idea that activated charcoal binds ethanol (it does not — charcoal does not adsorb small polar molecules like ethanol).

protocol

The most honest protocol the literature supports has three parts, ordered by effect size:

Before drinking. Eat a meal containing fat and protein — slows gastric emptying, blunts peak BAC, reduces hangover dose; this is the single largest controllable lever short of drinking less Penning et al. 2010. The prickly pear data — five hours pre-drinking dosing — is the strongest pre-emptive supplement signal, with the caveat that it is one moderate-sized trial Wiese et al. 2004.

During drinking. Pace alcohol with water (reduces total dose more reliably than it rehydrates), favour lighter-coloured spirits over dark over fortified wines (fewer congeners) Rohsenow & Howland 2010, stop earlier rather than later.

After. Sleep as long as possible (the sleep is poor but more is better than less Ebrahim et al. 2013). NSAIDs (ibuprofen 400 mg, naproxen 220–440 mg) treat headache, taken with food to limit gastric irritation. Carbohydrate-containing fluid (oral rehydration solution, fruit juice, broth) addresses both fluid loss and modest hypoglycaemia. Acetaminophen is contraindicated Whitcomb & Block 1994, Draganov et al. 2000. Time is the dominant variable: peak severity is at ~12 hours, resolution typically by 24.

contraindications

The contraindications are mostly attached to the cures, not the substance itself.

• Acetaminophen + alcohol — the load-bearing warning. Avoid acetaminophen entirely on drinking days and the day after, particularly in fasted state. The hepatotoxicity risk extends to regular moderate drinkers, not only heavy ones Draganov et al. 2000.
• NSAIDs + alcohol — additive gastric mucosal irritation and increased upper-GI bleeding risk. Avoid in known peptic ulcer disease, on anticoagulants, or with kidney disease.
• Hair of the dog — contraindicated in any person at risk of alcohol use disorder; a defining warning sign of dependence is morning drinking to relieve symptoms.
• Hangover painkiller use in pregnancy — both the substance (alcohol in pregnancy is contraindicated outright) and any cure attempt are out of scope; refer to obstetric care.
• Branded "anti-hangover" supplements — DHM and red ginseng products are not standardised; drug-supplement interactions are poorly studied. Particular caution in patients on warfarin or other anticoagulants (ginseng has weak interaction signals).

failure-modes

The dominant failure mode is the inversion of the hangover-cure problem: marketing-driven supplement use becomes the false reassurance that lets the drinker drink more. Branded products promise prevention, the user takes the pill before going out and treats it as licence; behaviour responds to the perceived safety net more than physiology does to the supplement. Trial evidence for this specific behavioural pathway in hangover supplements is thin, but the general "risk compensation" pattern in safety interventions is well-established.

Secondary failure modes: acetaminophen taken automatically out of habit (most consequential); reliance on the "I just need water" model when the hangover is in fact driven by acetaldehyde and inflammation, leading to repeated under-treatment; using exercise / sauna to "sweat it out" then worsening dehydration and orthostatic symptoms; hair-of-the-dog as a developing-dependence behavioural marker.

practicalities

Branded hangover supplements cost roughly $1–4 per dose (DHM-based products: Cheers, Flyby, Morning Recovery and similar), so a regular Friday-night user spends $50–200/year on a class with weak trial backing. NSAIDs and electrolyte powders are sub-dollar per dose. Korean pear juice, prickly pear capsules, and similar non-branded interventions are functionally cheap; the cost overhead is the branded-formulation tier.

Available without prescription in most jurisdictions. Many "hangover IV drip" clinic franchises bundle saline + B-vitamins + anti-emetic for $100–250 per session; the components are individually unobjectionable but no controlled trial supports IV rehydration over oral for this indication.

history

Hangover remedies are documented across millennia — pickled herring, raw egg yolk, bullshot, Bloody Mary, kaolin, prairie oyster — and none has been falsified by RCT because none has been formally tested. The Hangover Research Group, organised in the 2000s around the Verster lab and collaborators, is the first sustained scientific effort to characterise the syndrome rigorously and to test interventions Verster 2008, Penning et al. 2010. The branded-supplement industry expanded sharply in the late 2010s, riding the DHM preclinical work Shen et al. 2012 and venture-funded direct-to-consumer launches; the trial base did not expand proportionally.

stakes

What does not happen to a person who keeps treating their hangovers with acetaminophen and supplements: the drinking pattern doesn't change, because the perceived recovery cost stays low. The longevity literature on alcohol is clear that the lowest-risk dose is zero or close to it, and that even modest regular drinking elevates cardiovascular, cancer, and all-cause mortality. The honest cost of a hangover-cure-focused approach is that it can mask the dose-response signal — the body's protest that would otherwise prompt a re-evaluation — and in the acetaminophen case, can directly cause acute liver failure in an otherwise low-risk drinker.

payoff

The reader who understands what hangover cures can and can't do gains: (1) liver safety — they stop reaching for the Tylenol; (2) money saved — they stop buying the supplements that don't outperform a sandwich and a glass of water; (3) honest feedback — they stop using cures to drink past their tolerance and instead notice when their tolerance has shifted. The harder payoff is the meta one: the reader who internalises "there is no cure, only management and dose" tends, over months, to drink less, which is the only intervention the longevity literature actually backs.

out-of-scope

Adjacent topics this entry signposts to: the broader question of safe drinking limits and the J-curve / no-safe-dose debate (own entry); alcohol's effects on sleep architecture (own entry); ALDH2 deficiency and Asian flush (own entry); alcohol use disorder screening; acetaminophen safety more generally.

The credibility range

Optimist case. The trial base is thin because the field has been understudied, not because nothing works. Prickly pear shows a clean signal on an inflammatory mechanism that aligns with modern pathophysiology Wiese et al. 2004, van de Loo et al. 2020; DHM has strong preclinical mechanism work at GABA receptors Shen et al. 2012; Korean pear has positive small RCT data on acetaldehyde clearance Mun et al. 2015. Inflammatory modulators — NAC, curcumin, anti-cytokine compounds — are biologically plausible. Branded multi-ingredient formulas may produce real but small effects undetectable in 50-subject crossovers. Hydration, food, and sleep each have honest if modest effects. The skeptic conclusion "nothing works" is over-strong; the real conclusion is "modest gains are available, no cure exists, drink-less remains dominant."

Skeptic case. The 2005 BMJ review and the 2017 update reach the same verdict on a wider trial base: no convincing evidence of effective hangover prevention or treatment Pittler et al. 2005, Jayawardena et al. 2017. Most positive trials are single-site, small, and unreplicated; publication bias is severe in a supplement-funded literature; preclinical-to-human translation in this domain has been poor. The dominant marketed mechanism — "DHM rescues acetaldehyde" — is largely extrapolated from rats. The behavioural cost (false reassurance, more drinking, masked feedback) plausibly outweighs the marginal symptom relief. The only intervention with reliable signal is reduction in alcohol dose.

Author's call. The skeptic case is the working position, with three qualifications. (1) Pre-drinking food and pacing with water are real low-effort wins, not "cures" but genuine severity-reducers. (2) NSAIDs for headache the morning after are sensible and supported by mechanism; acetaminophen is the specific landmine. (3) Prickly pear has the cleanest positive trial and is biologically plausible; users who specifically want a pre-emptive supplement can take it with realistic expectations of a modest effect on the inflammatory subset of symptoms, not on headache. Everything else marketed as a "cure" is unsupported, sometimes expensive, and risks masking the only intervention that actually works. evidence scores at 3 — there is a real RCT literature with a Cochrane-adjacent systematic review, and the verdict is settled even if the verdict is "mostly negative." controversy scores at 2 — the supplement industry's marketing claims sit at odds with the trial base, but the academic field is largely aligned on the negative finding.

Stakeholder and incentive map

• Branded hangover-supplement industry — substantial commercial incentive to claim efficacy; venture-funded direct-to-consumer brands ($1–4/dose) have proliferated since the late 2010s DHM cycle. Their marketing typically cites the Shen 2012 rat paper without acknowledging the human-trial gap.
• IV-drip clinic chains — same incentive at a higher price point ($100–250/session); medical staffing lends a clinical aesthetic to a behaviourally compensatory intervention.
• Alcohol industry — quietly favours any framing that treats hangover as a manageable side-effect rather than the body's protest; "drink responsibly" plus an effective cure is the optimal commercial narrative.
• Academic researchers — the Alcohol Hangover Research Group — Verster's network at Utrecht and collaborators have driven the modern pathophysiology consensus. The group is principally funded by national research councils and has published the systematic reviews on which this entry rests.
• Clinical / public-health community — generally aligned with the negative trial conclusion; sees hangover-cure marketing as a low-stakes consumer-protection issue except for the acetaminophen-hepatotoxicity edge.
• Online community — Reddit, drinking-culture forums, and hangover-cure listicles strongly favour personal-testimonial mechanisms (electrolytes, IV drips, "Pedialyte protocol"). Volume is high; consistency is low; commercial sponsorship of supplement reviews is endemic.

Population variability

• ALDH2-deficient individuals (~540M people of East Asian ancestry) — disproportionately severe hangovers at small doses; no cure changes the underlying acetaldehyde-clearance bottleneck. The honest advice is dose minimisation; supplement makers target this population aggressively but RCTs in flush-positive populations are rare.
• Heavy / chronic drinkers — CYP2E1 induction makes acetaminophen specifically more dangerous; nutritional depletion increases hypoglycaemia risk; hair-of-the-dog use is a dependence marker.
• "Hangover-resistant" individuals — roughly 20–25% of drinkers report minimal or no hangover after demonstrably high blood alcohol levels in laboratory studies Hogewoning et al. 2016. The mechanism is unclear; this subgroup confounds self-report studies of cures.
• Women — generally higher peak BAC at equivalent dose due to body composition and gastric ADH differences; this affects dose, not the choice of cures.
• Older drinkers (60+) — slower hepatic clearance, more drug interactions, higher acetaminophen-hepatotoxicity risk, and steeper NSAID GI bleeding risk; the cure choice narrows.
• Pregnancy — out of scope; alcohol contraindicated.

Knowledge gaps

• Adequately powered, replicated RCTs of the branded DHM-based supplements at marketed doses, in real-world drinking patterns.
• Trials of anti-inflammatory pre-treatment (low-dose corticosteroids, curcumin, NAC) following the cytokine model van de Loo et al. 2020.
• Quantitative behavioural studies of whether hangover-supplement use increases drinking dose (the risk-compensation hypothesis).
• Pharmacokinetic studies of acetaminophen at therapeutic doses in moderate drinkers, to quantify the social-drinker hepatotoxicity risk more precisely than current case-series data.
• Mechanism work on the "hangover-resistant" phenotype Hogewoning et al. 2016 — if 20% of drinkers don't get hangovers, the protective factor is the most interesting unknown in the field.

Relation to brief. The brief named hair-of-the-dog, greasy food, rehydration, painkillers, and branded supplements; the article covers all five end-to-end (hair-of-the-dog in evidence + contraindications + failure-modes; food in protocol; rehydration in mechanism + misconceptions; painkillers as the load-bearing acetaminophen warning across misconceptions + contraindications; branded supplements across evidence + practicalities). No narrowing relative to the brief.

Category call. Placed under other rather than supplements or medical because the entry deliberately spans those categories — a hangover-cure entry under supplements would mis-signal that supplements are the centre of gravity (they aren't; the load-bearing finding is about acetaminophen plus alcohol). Open to recategorisation if a recovery or acute-symptoms category appears.

Rating difficulties. health_short_term was the hardest call. It is split between a negative health gain (avoiding acetaminophen hepatotoxicity, which is real and consequential) and the positive symptom relief from the rest of the protocol (which is small). Landed at 2 — the negative gain alone earns at least that. longevity at 1 is meta: the only longevity effect runs through the indirect channel of recalibrating drinking dose once the cure illusion is removed. I considered 0 and was talked out of it by the genuine acetaminophen-survival edge case.

Dream-narrative call. Overall score computes to ~26 (below the 40 obligatory threshold). Wrote one anyway — the relief / debunking lever is honestly present, and the dek and tagline benefit from compression around the "no cure exists; one of them hurts you" beat. The article body itself stays in straight reference voice; only the dek and tagline are dialled up.

Hard scoping decisions. Did not get into ALDH2 / Asian-flush genetics beyond a sentence, despite a real clinical dimension — that warrants its own entry, flagged in out-of-scope. Did not catalogue every branded product by name; named four of the most common DHM-based brands (Cheers, Flyby, Morning Recovery) and stopped, since the article is a class-level verdict, not a product review. Did not cover IV-drip clinic safety in depth; the relevant finding is the cost-vs-trial-base mismatch, not safety per se.

Separate-entry candidates flagged:

• Alcohol and longevity / the J-curve debunked — referenced indirectly in payoff; the actual evidence on lowest-risk dose warrants its own entry.
• Alcohol and sleep architecture — referenced in mechanism; the Ebrahim 2013 piece is a much deeper topic than a single citation deserves.
• ALDH2 deficiency / Asian flush — both a clinical pharmacology and a cancer-risk entry. Brief mention here; deserves its own slot.
• Acetaminophen safety — beyond the alcohol interaction. Dosing, the four-gram ceiling, the fasted-state risk, paediatric considerations.
• Alcohol use disorder screening (AUDIT) — implied by the hair-of-the-dog warning; would close the natural pointer from this entry.

Future-link candidates (entries to wire related to once they exist): alcohol-and-longevity, alcohol-and-sleep, aldh2-deficiency, acetaminophen-safety, audit-screening.

What I left out and why. Glutamine supplementation, milk thistle, kudzu, and a long tail of folk remedies — no controlled trials worth the column inches; mentioning each would dilute the central finding (which is that the trial base on the whole class is negative). The "drink milk before going out" tradition — no evidence; not worth retiring individually. Coffee as a hangover cure — caffeine masks fatigue but does not shorten hangover; folded implicitly under "nothing shortens it."

Voice call on the dek. Wrote it from the dream narrative even though score is below 40, because the relief lever is the entry's honest hook. The dek leads with the felt Saturday-morning scene before the trial-base verdict, per article.md §2a. Kept it citation-light per §2.